1. Market Research
  2. > Healthcare
  3. > Medical Facility Market Trends
  4. > CRO Quality Benchmarking Phase I Service Providers (6th edition)

CRO Quality Benchmarking Phase I Service Providers (6th edition)

  • May 2014
  • -
  • Industry Standard Research
  • -
  • 151 pages

This research, based on in-depth surveys collected from 113 pharmaceutical Phase I decision-makers, indicates that SGS Life Sciences out-performs customers’ expectations across a number of critical delivery drivers.

“Loyalty in the clinical research services industry is extraordinarily difficult to achieve,” explained Kevin Olson, CEO of Industry Standard Research. “The challenges associated with professional services industries and other highly regulated industries tend to lead to little differentiation among service providers. While SGS was not the only strong performer, their leadership across many Staff, Operational Excellence, and Financial factors place them in a very strong position,” Olson continued.

The 2014 CRO Quality Benchmarking – Phase I Service Providers report is a comprehensive, Consumer Reports-style assessment of Phase I service providers that captures buyers’ experiences from around the globe. It provides Phase I delivery quality data for the following 27 CROs:

• Biotrial
• CEDRA
• Celerion
• CHDR
• Chiltern
• Clinical Research Services (CRS)
• Covance
• DaVita
• DCRI-Duke
• Frontage
• HungaroTrial
• ICON
• INC Research
• inVentiv Health Clinical
• Medpace
• PAREXEL
• PPD
• PRA
• Premier Research
• Quintiles
• Quotient Clinical
• Rho
• SGS Life Sciences
• Siro Clinpharm
• Theorem
• US Oncology
• WCCT Global

The report provides delivery quality data across the following 27 dimensions:

Staff Characteristics

• Experience of the Phase I unit’s lead investigator
• Minimizing staff turnover
• Project manager quality
• Project team chemistry
• Responsiveness
• Scientific knowledge
• Therapeutic expertise

Operational Excellence

• Data quality
• Local market / Regulatory knowledge
• Meeting database lock timelines
• Meeting first patient / first visit timelines
• Meeting overall project timelines
• Offered innovative solutions
• Patient / volunteer recruitment
• Speed of site start-up
• Technology for real-time access to data
• Timely project communications
• Up-front contingency planning, risk management

Organizational & Finance Characteristics

• Access to “unique” tests, machines, equipment
• Access to a broad range of services beyond clinic / volunteer management
• Access to patient populations
• Financial strength / stability
• Location of Phase I unit(s) in different global regions
• Location of Phase I unit(s) within your country
• Low cost
• Minimizing change orders
• Timely access to open bed / clinic space

Table Of Contents

CRO Quality Benchmarking Phase I Service Providers (6th edition)
Copyright and Usage Guidelines 6
Introduction 7
Methodology 8
Respondent Demographics and Qualifications 9
Participant Years of Industry Experience 9
Participant Geography 9
Participant Company Size 9
Number of Ratings per Company 10
Major Sections 11
Outsourcing Behaviors, Attitudes, Beliefs, and Intentions 12
Phase I Leaders, Unprompted 13
Phase I Leaders, Prompted 14
Proposal Volume 15
Service Provider Usage 16
Service Provider Preference 17
Service Provider Cost Experience 18
Summary Table 19
Service Provider Selection Drivers 20
Most Important Service Provider Attributes 21
Service Provider Attributes Gaining Importance 23
Service Provider Performance and Scorecards Across Attributes 24
Figure 1 - “Staff Characteristics” Ratings 26
Figure 2 - “Operational Excellence” Ratings 27
Figure 3 - “Organizational and Finance” Ratings …… 28
Performance Summary by Category 29
Service Provider Loyalty 30
Company Service Quality Profiles 32
Celerion 34
Clinical Research Services (CRS) 35
Covance 36
ICON 37
INC Research 38
inVentiv Health Clinical 39
Medpace 40
PAREXEL 41
PPD 42
PRA 43
Premier Research 44
Quintiles 45
Quotient Clinical 46
SGS Life Sciences 47
US Oncology 48
WCCT Global 49
Phase I Study Data 50
Phase I Leaders, Unprompted 51
Phase I Leaders, Prompted 53
Proposal Volume 54
Most Important Service Provider Attributes 55
Service Provider Attributes Gaining Importance 56
Service Provider Usage 57
Service Provider Preference 58
Best Service Provider at Differentiation 59
Service Provider Cost Experience 60
Service Provider Cost Experience Among Users in Past 18 Months 61
Service Provider Cost Experience Among Lapsed Users and Non-users 62
Service Provider Cost Perceptions 63
Service Provider Budget Allocation 64
Outsourcing Volume Past 12 months 65
Outsourcing Volume Next 12 months 66
Service Provider Loyalty 67
Service Provider Loyalty 67
Service Provider Loyalty - Past 3 Years 68
Service Provider Loyalty - Rolling Average 69
Service Provider Loyalty - Company Size 70
Overall Satisfaction with Service Providers 71
Willingness to Recommend Service Providers 72
Likelihood to Use Service Providers Again 73
Service Provider Drill-downs 74
Biotrial Use and Satisfaction 74
Biotrial Performance Against Expectations 75
CEDRA Use and Satisfaction 76
CEDRA Performance Against Expectations 77
Celerion Use and Satisfaction 78
Celerion Performance Against Expectations 79
CHDR Use and Satisfaction 80
CHDR Performance Against Expectations 81
Chiltern Use and Satisfaction 82
Chiltern Performance Against Expectations 83
Clinical Research Services (CRS) Use and Satisfaction 84
Clinical Research Services (CRS) Performance Against Expectations 85
Covance Use and Satisfaction 86
Covance Performance Against Expectations 87
DaVita Use and Satisfaction 88
DaVita Performance Against Expectations 89
DCRI-Duke Use and Satisfaction 90
DCRI-Duke Performance Against Expectations 91
Frontage Use and Satisfaction 92
Frontage Performance Against Expectations 93
HungaroTrial Use and Satisfaction 94
HungaroTrial Performance Against Expectations 95
ICON Use and Satisfaction 96
ICON Performance Against Expectations 97
INC Research Use and Satisfaction 98
INC Research Performance Against Expectations 99
inVentiv Health Clinical Use and Satisfaction 100
inVentiv Health Clinical Performance Against Expectations 101
Medpace Use and Satisfaction 102
Medpace Performance Against Expectations 103
PAREXEL Use and Satisfaction 104
PAREXEL Performance Against Expectations 105
PPD Use and Satisfaction 106
PPD Performance Against Expectations 107
PRA Use and Satisfaction 108
PRA Performance Against Expectations 109
Premier Research Use and Satisfaction 110
Premier Research Performance Against Expectations 111
Quintiles Use and Satisfaction 112
Quintiles Performance Against Expectations 113
Quotient Clinical Use and Satisfaction 114
Quotient Clinical Performance Against Expectations 115
Rho Use and Satisfaction 116
Rho Performance Against Expectations 117
SGS Life Sciences Use and Satisfaction 118
SGS Life Sciences Performance Against Expectations 119
Siro Clinpharm Use and Satisfaction 120
Siro Clinpharm Performance Against Expectations 121
Theorem Use and Satisfaction 122
Theorem Performance Against Expectations 123
US Oncology Use and Satisfaction 124
US Oncology Performance Against Expectations 125
WCCT Global Use and Satisfaction 126
WCCT Global Performance Against Expectations 127
Cross-service provider performance 128
Access to “unique” tests, machines, equipment 128
Access to a broad range of services 129
Access to patient populations 129
Data quality 130
Experience of the Phase I unit's lead investigator 130
Financial strength / stability 131
Local market / Regulatory knowledge 131
Location of Phase I unit(s) in different global regions 132
Location of Phase I unit(s) within your country 132
Low cost 133
Meeting database lock timelines 133
Meeting first patient / first visit timelines 134
Meeting overall project timelines 134
Minimizing change orders 135
Minimizing staff turnover 135
Offered innovative solutions 136
Patient / volunteer recruitment 136
Project manager quality 137
Project team chemistry 137
Responsiveness 138
Scientific knowledge 138
Speed of site start-up 139
Technology for real-time access to data 139
Therapeutic expertise 140
Timely access to open bed / clinic space 140
Timely project communications 141
Up-front contingency planning, risk management 141
Sponsor Preferences 142
Scenario Trade-offs 142
Service Provider Input Usefulness 143
Respondent Demographics 144
Company Type 144
Primary Area of Responsibility 145
Outsourcing Responsibility 146
Job Title 146
Recent Activity in Outsourced Activities 147
Phase Responsibility 147
Involvement in Clinical Development Process 148
Years in the Industry 149
Location 149
Therapeutic Area 150
About Industry Standard Research 151

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Global Tumor Marker Diagnostic Testing Market: Future Horizons and Growth Strategies--Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

Global Tumor Marker Diagnostic Testing Market: Future Horizons and Growth Strategies--Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

  • $ 21100
  • Industry report
  • August 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. Highlights - Identifies and evaluates major business opportunities emerging in the tumor marker market during ...

2016 Competing in the Global Cancer Diagnostics Market

2016 Competing in the Global Cancer Diagnostics Market

  • $ 21100
  • Industry report
  • October 2016
  • by Venture Planning Group

This new VPGMarketResearch.com comprehensive seven-country study identifies and evaluates major business opportunities emerging in the cancer diagnostics market during the next five years; examines trends ...

Tumor Markers 2020: Reagents and Instrumentation--Supplier Shares and Strategies, Country Segment Forecasts, Emerging Opportunities

Tumor Markers 2020: Reagents and Instrumentation--Supplier Shares and Strategies, Country Segment Forecasts, Emerging Opportunities

  • $ 21100
  • Industry report
  • October 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. Highlights - Identifies and evaluates major business opportunities emerging in the tumor marker market during ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.